Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer

BJU International

Volumn 114, Issue 3, 2014, Pages 344-353

  Denham, James W ^a   Nowitz, Michael ^b   Joseph, David ^c   Duchesne, Gillian ^d   Spry, Nigel A ^c   Lamb, David S ^e   Matthews, John ^f   Turner, Sandra ^g   Atkinson, Chris ^h   Tai, Keen Hun ^d   Gogna, Nirdosh Kumar ⁱ   Kenny, Lizbeth ^j   Diamond, Terry ^k   Smart, Richard ^l   Rowan, David ^m   Moscato, Pablo ⁿ   Vimieiro, Renato ⁿ   Woodfield, Richard ^o   Lynch, Kevin ^o   Delahunt, Brett ^p   Murray, Judy ^e   D'Este, Cate ^q   McElduff, Patrick ^a   Steigler, Allison ^a   Kautto, Allison ^a   Ball, Jean ^a   more..

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b Pacific Radiology   (New Zealand)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e WELLINGTON HOSPITAL   (New Zealand)

^f AUCKLAND CITY HOSPITAL   (New Zealand)

^g WESTMEAD HOSPITAL   (Australia)

^h St Georges Cancer Care Centre   (New Zealand)

ⁱ PRINCESS ALEXANDRA HOSPITAL   (Australia)

^j ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^k ST GEORGE HOSPITAL   (Australia)

^l UNIVERSITY OF NEW SOUTH WALES   (Australia)

^m Southern Radiology   (Australia)

ⁿ UNIVERSITY OF NEWCASTLE   (Australia)

^o BioMarin Pharmaceutical Australia Pty Ltd   (Australia)

^p UNIVERSITY OF OTAGO   (New Zealand)

^q UNIVERSITY OF NEWCASTLE   (Australia)

more..

Author keywords

androgen suppression; bisphophonate; bone mineral density; fractures; prostate cancer

Indexed keywords

LEUPRORELIN; ZOLEDRONIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE DENSITY; CANCER STAGING; CONTROLLED STUDY; DRUG EFFICACY; FOLLOW UP; HISTOLOGY; HUMAN; INCIDENCE; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SPINE FRACTURE; TREATMENT DURATION; TREATMENT RESPONSE;

ANDROGEN SUPPRESSION; BISPHOPHONATE; BONE MINERAL DENSITY; FRACTURES; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; AUSTRALIA; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NEW ZEALAND; PROSTATIC NEOPLASMS; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 84906940239     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12497     Document Type: Article

References (46)

1. Granfors T, Modig H, Damber J-E, Tomic R,. Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone. J Urol 2006; 176: 544-547 (Pubitemid 43927879)
2. Pilepich MV, Winter K, Lawton C, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61: 1285-1290 (Pubitemid 40470408)
3. Pilepich MV, Winter K, John MJ, et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-1252 (Pubitemid 32727802)
4. D'Amico AV, Chen M-H, Renshaw AA, Loffredo M, Kantoff PW,. Androgen suppression and radiation vs radiation alone for prostate cancer. JAMA 2008; 299: 289-295 (Pubitemid 351159365)
5. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-108 (Pubitemid 34786197)
6. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005; 6: 841-850 (Pubitemid 41614795)
7. Bolla M, De Reijke TM, van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360: 2516-2527
8. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26: 2497-2504
9. Freedland SJ, Eastham J, Shore N,. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. Prostate Cancer Prostatic Dis 2009; 12: 333-338
10. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G,. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997; 79: 933-941 (Pubitemid 28316762)
11. Galvao DA, Taaffe DR, Spry N, Joseph D, Turner D, Newton RU,. Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis 2009; 12: 198-203
12. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS,. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-164 (Pubitemid 40096612)
13. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24: 3979-3983 (Pubitemid 46630747)
14. Stoch SA, Parker RA, Chen L, et al. Bone loss in men with prostate cancer treated with gonadotropin- releasing hormone agonists. J Clin Endocrinol Metab 2001; 86: 2787-2791 (Pubitemid 32545740)
15. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT,. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181-186
16. Chen Z, Maricic M, Nguyen P, Ahmann FR, Bruhn R, Dalkin BL,. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer 2002; 95: 2136-2144 (Pubitemid 35253375)
17. Daniell HW,. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157: 439-444 (Pubitemid 27026812)
18. Kiratli BJ, Srinivas S, Perkash I, Terris MK,. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001; 57: 127-132 (Pubitemid 32065833)
19. Ryan CW, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT,. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer druing first year of therapy. Urology 2007; 70: 122-126 (Pubitemid 47081101)
20. Diamond TH, Higano CS, Smith MR, Singer FR,. Osteoporosis in men with prostate cancer receiving androgen deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004; 100: 892-899 (Pubitemid 38222847)
21. Melton LJ, Alothman KI, Khosla S, Achenbach SJ, Oberg AL, Zincke H,. Fracture risk following bilateral orchiectomy. J Urol 2003; 169: 1747-1750 (Pubitemid 36443487)
22. Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011; 12: 451-459
23. Lee MV, Fong EM, Singer FR, Guenette RS,. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001; 61: 2602-2608 (Pubitemid 32685845)
24. Neville-Webbe HL, Holen I, Coleman RE,. The anti-tumour activity of bisphosphonates. Cancer Treat Rev 2002; 28: 305-319 (Pubitemid 36054539)
25. Boissier S, Magnetto S, Frappart L, et al. Bisphosphates inhibit prostate and breast carcinoma cell adhesion to unmineralised and mineralised bone extracellular matrices. Cancer Res 1997; 57: 3890-3894 (Pubitemid 27427670)
26. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468
27. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N,. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008-2012 (Pubitemid 36576705)
28. Shao Y-H, Moore DF, Shih W, Lin Y, Jang TL, Lu-Yao GL,. Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU Int 2013; 111: 745-752
29. Smith MR,. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer 2003; 97 (3 Suppl.): 789-795 (Pubitemid 36125814)
30. Eastell R, Cedel SL, Wahner HW, Riggs BL, Melton JL,. Classification of vertebral fractures. J Bone Miner Res 1991; 63: 207-215
31. Genant HK,. Assessment of vertebral fractures in osteoporosis research. J Rheumatol 1997; 24: 1212-1214 (Pubitemid 27250138)
32. StataCorp. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP, 2009
33. Vallarta-Ast N, Krueger D, Wrase C, Agrawal S, Binkley N,. An evaluation of densitometric vertebral fracture assessment in men. Osteoporos Int 2007; 18: 1405-1410 (Pubitemid 47389463)
34. Ferrar L, Jiang G, Cawthon PM, et al. Identification of vertebral fracture and non-osteoporotic short vertebral height in men: the MrOS Study. J Bone Miner Res 2007; 22: 1434-1441 (Pubitemid 351339688)
35. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL,. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 7897-7903 (Pubitemid 46657388)
36. Nguyen TV, Eisman JA, Kelly PJ, Sambrook PN,. Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol 1996; 144: 255-263 (Pubitemid 26313502)
37. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007; 18: 1033-1046 (Pubitemid 47020000)
38. Frost M, Abrahamsen B, Masud T, Brixen K,. Risk factors for fracture in elderly men: a population-based prospective study. Osteoporos Int 2012; 23: 521-531
39. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007; 25: 1038-1042 (Pubitemid 46596753)
40. Smith MR, Egerdie B, Toriz NH, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745-755
41. Smith MR, Morton RA, Barnette KG, et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol 2010; 184: 1316-1321
42. Seeman E,. Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy? [Review] Bone 2007; 41: 308-317 (Pubitemid 47199158)
43. Stone KL, Seeley DG, Lui LY, et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 2003; 18: 1947-1954 (Pubitemid 37377443)
44. Szulc P, Munoz F, Duboeuf F, Marchand F, Delmas PD,. Bone mineral density predicts osteoporotic fractures in elderly men: the MINOS study. Osteoporos Int 2005; 16: 1184-1192 (Pubitemid 41396945)
45. Campbell SC, Bhoopalam N, Moritz TE, et al. The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis. Urology 2010; 75: 1138-1143
46. Shahinian VB,. Reducing fracture risk in men on androgen deprivation therapy. Nat Rev Urol 2011; 8: 9-10